2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Mini-Oral Session

[MO38] Mini-Oral Session 38　Cross-sectional Program 4（PhaseⅠ trial and Precision medicine）
【E】

Sat. Feb 19, 2022 9:10 AM - 10:00 AM Room 7 (Room E, 1F, Kyoto International Conference Center)

Chair：Takafumi Koyama（Department of Experimental Therapeutics, National Cancer Center Hospital），Akira Hirasawa（Department of Clinical Genomic Medicine, Graduate School oF Medicine, Dentistry and Pharmaceutical Sciences, Okayama University）

[MO38-1] Phase I study of BI 836880 alone or combined with ezabenlimab in Japanese patients (pts) with advanced solid tumors

○Kentaro Yamazaki1, Takafumi Koyama2, Toshio Shimizu2, Akiko Todaka1, Takeshi Kawakami1, Jangsoo Yoon3, Damijan Erzen4, Jianrui Hou3, Noboru Yamamoto2 (1.Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 2.Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, 3.Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan, 4.Boehringer Ingelheim GmbH, Ingelheim, Germany)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password